Skip to main content

Advertisement

SpringerLink
Log in

Chronic inflammatory demyelinating polyneuropathies: Current treatment strategies

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Chronic inflammatory demyelinating polyradiculopathy (CIDP), considered an immune-mediated disease, is likely under-recognized and under-treated due to its heterogeneous presentation and the limitations of clinical, serologic, and electrophysiologic diagnostic criteria. Despite these limitations, early diagnosis and treatment is important in preventing irreversible axonal loss and improving functional recovery. Primary treatment modalities include intravenous immunoglobulin and plasmapheresis, for which there is randomized, double-blind, placebo-controlled evidence. In addition, despite less definitive published evidence of efficacy, corticosteroids are considered standard therapies because of their long history of use. Studies have failed to demonstrate a difference in efficacy among these three treatments; consequently, the choice is usually based on availability and side-effect profile. A number of chemotherapeutic and immunosuppressive agents have also shown to be effective in treating CIDP but significant evidence is lacking; therefore, these agents are primarily used in conjunction with other modalities. Regardless of the treatment choice, long-term therapy is required to maintain a response and prevent relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dyck PJ, Lais AC, Ohta M, et al.: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975, 50:621–637.

    PubMed  CAS  Google Scholar 

  2. Toyka KV, Gold R: The pathogenesis of CIDP, rational for treatment with immunomodulatory agents. Neurology 2003, 60(Suppl 3):S2–S7.

    PubMed  CAS  Google Scholar 

  3. Koller H, Schroeter M, Kieseier BC, Hartung HP: Chronic inflammatory demyelinating polyneuropathy — update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol 2005, 18:273–278.

    Article  PubMed  Google Scholar 

  4. McLeod JG, Pollard JD, Macaskill P, et al.: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999, 46:910–913.

    Article  PubMed  CAS  Google Scholar 

  5. Mygland A, Monstadt P: Chronic polyneuropathies in Vest-Agder Norway. Eur J Neurol 2001, 8:157–165.

    Article  PubMed  CAS  Google Scholar 

  6. Latov N: Diagnosis of CIDP. Neurology 2002, 59(Suppl 6):S2–S6.

    PubMed  Google Scholar 

  7. Briani C, Brannagan TH, Trojaborg W, Latov N: Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 1996, 6:311–325.

    Article  PubMed  CAS  Google Scholar 

  8. Cornblath DR, Feasby TE, Hahn AF, et al.: Research criteria for diagnosis of chronic inflammatory demeyelianting polyneuropathy (CIDP). Neurology 1991, 41:617–618.

    Google Scholar 

  9. Hattori N, Misu K, Koike H, et al.: Age of onset influences clinical features of chronic inflammatory demeylinating polyneuropathy. J Neurol Sci 2001, 184:57–63.

    Article  PubMed  CAS  Google Scholar 

  10. Hughes R, Bensa S, Willison H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.

    Article  PubMed  CAS  Google Scholar 

  11. The Neuropathy Association, Medical Advisory Committee: Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Periph Nervous Syst 2003, 8:282–284.

    Article  Google Scholar 

  12. Nicolas G, Miasonobe T, Le Forestier N, et al.: Proposed revised electrophysiological criteria for chronic inflammatory demeylinating polyradiculoneuropathy. Ann Neurol 2002, 25:26–30.

    Google Scholar 

  13. Thiasetthawatkul P, Logogian EL, Herrmann DN: Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002, 59:1526–1532.

    Google Scholar 

  14. Magda P, Latov N, Brannagan TH, et al.: Comparison of the electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2003, 60:1755–1759.

    Article  PubMed  Google Scholar 

  15. Saperstein DS, Barohn RJ: Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep 2003, 3:57–63.

    Article  PubMed  Google Scholar 

  16. Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343–1356.

    Article  PubMed  Google Scholar 

  17. Nobile-Orazio E: Multifocal motor neuropathy. J Neuroimmunol 2001, 115:4–18.

    Article  PubMed  CAS  Google Scholar 

  18. Saperstein DS, Amato AA, Wolfe GI, et al.: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560–566.

    Article  PubMed  CAS  Google Scholar 

  19. Kuwabara S, Misawa S, Kanai K, et al.: Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006, 66:105–107.

    Article  PubMed  CAS  Google Scholar 

  20. Dyck PJ, Engelstad J, Dispenzieri A: Vascular endothelial growth factor and POEMS. Neurology 2006, 66:10–12.

    Article  PubMed  Google Scholar 

  21. Carpo M, Allaria S, Scarlato G, Nobile-Orazio E: Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy. Neurology 1999, 53:2206–2207.

    PubMed  CAS  Google Scholar 

  22. Brannagan TH: Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002, 59:S33–S40.

    Article  PubMed  CAS  Google Scholar 

  23. Van Doorn PA, Brand A, Strengers PF, et al.: High-dose immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, crossover study. Neuology 1990, 40:209–212.

    Google Scholar 

  24. Hahn AF, Bolton CF, Zochodne D, Faesby TE: Intravenous immunoglobulin treatment in chronic inflammatory polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 1996, 119:1067–1077.

    Article  PubMed  Google Scholar 

  25. Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449.

    PubMed  CAS  Google Scholar 

  26. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.

    Article  PubMed  Google Scholar 

  27. Dyck PJ, O’Brien PC, Ovaitt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.

    Article  PubMed  CAS  Google Scholar 

  28. Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838–845.

    Article  PubMed  CAS  Google Scholar 

  29. Pachner AR: Immunosuppressive therapy: targeting the autoantigen in neurologic disease. Adv Neurol 1997, 4:3–8.

    Google Scholar 

  30. McCombe PA, Pollard JD, McLeod JG: Chonic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiologic study of 92 cases. Brain 1987, 110:1617–1630.

    Article  PubMed  Google Scholar 

  31. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878–884.

    PubMed  CAS  Google Scholar 

  32. Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, CD002062.

  33. Veenstra DL, Best JH, Hornberger J, et al.: Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999, 33:829–839.

    PubMed  CAS  Google Scholar 

  34. Zonana-Nacach A, Barr SG, Magder LS, Petri M: Damage in systemic lupus erythematous and its association with corticosteroids. Arthritis Rheum 2000, 43:1801–1808.

    Article  PubMed  CAS  Google Scholar 

  35. Ropper AH: Current treatments of CIDP. Neurology 2003, 60(Suppl 3):S16–S22.

    PubMed  CAS  Google Scholar 

  36. van Schaik IN, Winer JB, de Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, CD001797.

  37. Federico P, Zochodne DW, Hahn AF, et al.: Multifocal motor neuropathy improved by IVIg. Randomized double-blind, placebo-controlled study. Neurology 2000, 55:12 56–12 62.

    CAS  Google Scholar 

  38. Leger JM, Chassande B, Musset L, et al.: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124:145–153.

    Article  PubMed  CAS  Google Scholar 

  39. Azulay JP, Blin O, Pouget J, et al.: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994, 44:429–432.

    PubMed  CAS  Google Scholar 

  40. van den Berg LH, Kerkhoff H, Oey PL, et al.: Treatment of multifocal motor neuropathy with high dose intravenous immuno-globins: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995, 59:248–252.

    PubMed  Google Scholar 

  41. Koski CL: Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002, 59(Suppl 6):S22–S27.

    PubMed  CAS  Google Scholar 

  42. Dalakas MC, Quarles RH, Farrer RG, et al.: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IGM gammopathy. Ann Neurol 1996, 40:792–795.

    Article  PubMed  CAS  Google Scholar 

  43. Comi G, Roveri L, Swan A, et al.: A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002, 249:1370–1377.

    Article  PubMed  CAS  Google Scholar 

  44. Nobile-Orazio E, Meucci N, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123:710–717.

    Article  PubMed  Google Scholar 

  45. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996, 47:674–677.

    PubMed  Google Scholar 

  46. Vucic S, Black KR, Chong PS, Cros D: Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004, 63:1264–1269.

    PubMed  Google Scholar 

  47. National Institutes of Health Consensus Conference: Intravenous immune globulin: prevention and treatment of disease. JAMA 1990, 264:3189–3193.

  48. Center of Disease Control and Prevention: Renal insufficiency and failure associated with immune globulin intravenous therapy — United States, 1985–1998. Morb Mortal Wkly Rep 1999, 35:231–233.

    Google Scholar 

  49. Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory polyradiculoneuropathy. Cochrane Database Syst Rev 2004, CD003906.

  50. Heininger K, Liebert UG, Toyka KV, et al.: Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984, 66:1–14.

    Article  PubMed  CAS  Google Scholar 

  51. Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.

    Article  PubMed  CAS  Google Scholar 

  52. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.

    Article  PubMed  Google Scholar 

  53. Blume G, Pestronk A, Goodnough LT: Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plamsa exchange and IV cyclophosphamide. Neurology 1995, 45:1577–1580.

    PubMed  CAS  Google Scholar 

  54. Carpo M, Cappellari A, Mora G, et al.: Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998, 50:1480–1482.

    PubMed  CAS  Google Scholar 

  55. Hughes RA, Bouche P, Cornblath DR, et al.: European Federation of Neurologic Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurologic Societies and the Peripheral Nerve Society. Eur J Neurol 2006, 13:326–332.

    Article  PubMed  CAS  Google Scholar 

  56. Barrnett MH, Pollard JD, Davies L, McLeod JG: Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454–460.

    Article  Google Scholar 

  57. Mahattanakul W, Crawford TO, Griffin JW, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporine-A. J Neurol Neurosurg Psychiatry 1996, 60:185–187.

    PubMed  CAS  Google Scholar 

  58. Matsuda M, Hoshi K, Gono T, et al.: Cyclosporin A in treatment of of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004, 224:29–35.

    Article  PubMed  CAS  Google Scholar 

  59. Ahlmen J, Anderson O, Hallgren G, Peilot B: Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998, 30:4194.

    Article  PubMed  CAS  Google Scholar 

  60. Good JL, Chehrenama M, Mayer RF, Koski CL: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.

    PubMed  CAS  Google Scholar 

  61. Brannagan TH, Pradhan A, Heiman-Patterson T, et al.: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002, 58:1856–1858.

    PubMed  CAS  Google Scholar 

  62. Pentland B: Azathioprine in chronic relapsing idiopathic polyneuropathy. Postgrad Med J 1980, 56:734–735.

    Article  PubMed  CAS  Google Scholar 

  63. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.

    PubMed  CAS  Google Scholar 

  64. Dyck PJ, O’Brien P, Swanson C, et al.: Combined azathioprine and prednisone in chronic inflammatory-demyelinating ployneuropathy. Neurology 1985, 35:1173–1176.

    PubMed  CAS  Google Scholar 

  65. Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory polyradiculoneuropathy. Cochrane Database Syst Rev 2004, CD003280.

  66. Ho S, Clipstone N, Timmermann L, et al.: The mechanism of action of cyclosporine A and FK506. Clin Immunol Immunopathol 1996, 80:S40–45.

    Article  PubMed  CAS  Google Scholar 

  67. Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM: Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2005, CD003217.

  68. Brock N, Stekar J, Pohl J, et al.: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittelforschung 1979, 29:659–661.

    PubMed  CAS  Google Scholar 

  69. Gladstone DE, Prestrud AA, Brannagan TH: High-dose cyclophosphamide results in long-term disease remission with restoration of normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005, 10:11–16.

    Article  PubMed  CAS  Google Scholar 

  70. Bouchard C, Lacroix C, Plante V, et al.: Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 2005, 5:242–245.

    Google Scholar 

  71. Brannagan TH, Aleadini A, Gladstone DE: High-dose cyclophosphamide without stem-cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006, In press.

  72. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA: Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol 1999, 230(Suppl):111–115.

    Article  CAS  Google Scholar 

  73. Dalakas MC, Engel WK: Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981, 9:S134–S145.

    Article  Google Scholar 

  74. McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain 1987, 110:1617–1630.

    Article  PubMed  Google Scholar 

  75. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2–3):85–118.

    Article  PubMed  CAS  Google Scholar 

  76. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.

    PubMed  CAS  Google Scholar 

  77. Benedetti L, Grandis M, Nobbio L: Mycophenylate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004, 29:748–749.

    Article  PubMed  Google Scholar 

  78. Hadden RD, Sharrack B, Bensa S, et al.: Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999, 53:57–61.

    PubMed  CAS  Google Scholar 

  79. Grillo-Lopez AJ: Rituximab: an insider’s historical perspective. Semin Oncol 2000, 276(6 Suppl 12):9–16.

    Google Scholar 

  80. Briani C, Zara G, Zambello R, et al.: Rituximab-responsive CIDP. Eur J Neurol 2004, 11:788.

    Article  PubMed  CAS  Google Scholar 

  81. Knecht H, Blumberger M, Tobon A, Steck A: Sustained remission of CIDP associated with Evans syndrome. Neurology 2004, 63:730–732.

    PubMed  Google Scholar 

  82. Bodley-Scott DD: Chronic inflammatory demyelinating polyradiculoneuropathy responding to rituximab. Practical Neurol 2005, 5:242–245.

    Article  Google Scholar 

  83. Latov N, Sherman WH, Vlahides G: Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan. Neurology 1999, 52:A551.

    Google Scholar 

  84. Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion therapy using Rituximab. Neurology 1999, 52:1701–1704.

    PubMed  CAS  Google Scholar 

  85. Pestronk A, Florence J, Miller T, et al.: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003, 74:485–489.

    Article  PubMed  CAS  Google Scholar 

  86. Kilidireas C, Anagnostopoulus A, Karandreas N, et al.: Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006, 47:859–864.

    Article  PubMed  CAS  Google Scholar 

  87. Hirst C, Raasch S, LLewelyn G, Robertson N: Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006, 77:800–802.

    Article  PubMed  CAS  Google Scholar 

  88. Khanna D, McMahon M, Furst DE: Safety of tumour necrosis factor-alpha antagonists. Drug Safety 2004, 27:307–324.

    Article  PubMed  CAS  Google Scholar 

  89. Chin RL, Sherman WH, Sander HW, et al.: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003, 310:19–21.

    Article  CAS  Google Scholar 

  90. Choudhary PP, Thompson N, Hughes RA: Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995, 242:252–253.

    Article  PubMed  CAS  Google Scholar 

  91. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al.: Interferon-beta 1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 53:1364–1365.

    PubMed  CAS  Google Scholar 

  92. Radziwill AJ, Kuntzer T, Fuhr P, Steck AJ: Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-b1a) and intravenous immunoglobulin (IVIg). J Neurol Neurosurg Psychiatry 2001, 70:273.

    Google Scholar 

  93. Vallet JM, Hahn AF, Léger JM, et al.: Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003, 60(Suppl 8):23–28.

    Google Scholar 

  94. Gorson KC, Ropper AH, Clark BD, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998, 50:84–87.

    PubMed  CAS  Google Scholar 

  95. Pavesi JW, Cattaneo L, Marbini A, et al.: Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002, 249:777–779.

    Article  PubMed  Google Scholar 

  96. McCrone P, Chisholm D, Knapp M, et al.: Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003, 6:687–694.

    Article  Google Scholar 

  97. Gorson KC, Amato AA, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without monoclonal gammopathy. Neurology 1997, 48:321–328.

    PubMed  CAS  Google Scholar 

  98. De Sousa EA, Brannagan TH: Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2006, 8:91–103.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Weill Medical College of Cornell University, Peripheral Neuropathy Center, 635 Madison Avenue, Suite 400, New York, NY, 10022, USA

    Thomas H. Brannagan III MD

Authors
  1. Thomas B. Toothaker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas H. Brannagan III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas H. Brannagan III MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toothaker, T.B., Brannagan, T.H. Chronic inflammatory demyelinating polyneuropathies: Current treatment strategies. Curr Neurol Neurosci Rep 7, 63–70 (2007). https://doi.org/10.1007/s11910-007-0023-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-007-0023-5

Keywords

Search

Navigation